BDTX
Black Diamond Therapeutics
1 day chart
About BDTX
Black Diamond Therapeutics, Inc. is a precision oncology medicine company. The Company is focused on the discovery and development of small molecule, MasterKey therapies. It builds a pipeline of small molecule kinase inhibitors that target a range of driver mutations in cancer. Its technology platform, Mutation-Allostery-Pharmacology (MAP) platform is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Its lead product candidate, BDTX-189, is designed as an orally available, irreversible small molecule inhibitor that targets a spectrum of 48 non-canonical and canonical driver mutations of the ErbB kinases epidermal growth factor receptor (EGFR) & HER2. BDTX-1535 is a brain-penetrant inhibitor that targets a spectrum of EGFR mutations, including allosteric and canonical mutations. It also has early-stage programs, such as B-Raf Proto-Oncogene (BRAF), and fibroblast growth factor receptor (FGFR).
Buy US stocks in Australia starting with BDTX. Open an account and start investing today!
$66.40M
-
0.00%
78.79K
$1.86
$1.76
$1.81
$4.08
$1.18
BDTX FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in BDTX
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.